A new AARP report shows that 25 of the top Medicare Part D drugs have nearly doubled in price.
According to the report, this group of brand-name drugs has seen an average lifetime price hike of 98% since they first became available.
These drugs account for nearly $50 billion in total Medicare Part D spending and are being used by more than 7 million Part D enrollees. They are the top medications that have not yet been selected for medicare price negotiation.
"We’re hearing about more and more people who are having to choose between their prescription drugs and other important things, like their rent or paying for food," said Leigh Purvis, prescription drug policy principal for the AARP Public Policy Institute.
The majority of the drugs in this list treat conditions like diabetes and cancer.